Project Grant HT94252410695
Award Date
8/1/24
Completion Date
7/31/27
Dollars Obligated
$1.6M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This federal Project Grant award, with a funding amount of $154,084.00, was granted by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports research by the University of Texas Health Science Center at Houston (UTHealth) to explore aberrant alternative cleavage and polyadenylation linked to RB1 mutations in the development of osteosarcoma. The research aims to transform healthcare for military service members, veterans, and the...
The University of Texas Health Science Center at Houston (UTHealth) was awarded a $1,559,997 Project Grant by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports a pharmacology and efficacy study of a novel, blood-brain barrier (BBB)-permeable agent for the treatment of breast cancer brain metastases. The project will be conducted over a 3-year period from September 1, 2024 to August 31, 2027. The Military...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $544,892 to the University of Texas Health Science Center at Houston to develop a novel peptide-drug conjugate for precision-targeted DNA damage in neuroendocrine tumors. The award commenced on August 1, 2025 and is set to conclude on July 31, 2028. The goal of this research is to transform healthcare for military service members, veterans, and the broader...
The University of Texas Health Science Center at Houston (UTHealth) received a $3,845,822 Project Grant award from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to conduct a comparative effectiveness study on transdiagnostic behavior therapy versus treatment-as-usual for adjustment disorder following traumatic event exposure. The award runs from July 1, 2024 to June 30, 2028. The federal grant supports innovative biomedical research initiatives aimed at...
The federal Project Grant award, with ID HT94252410992, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, totaling $2,710,479.00, will fund a research initiative led by the University of Texas M.D. Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The award's performance period is from August 15, 2024 to...
The University of Texas Health Science Center at San Antonio received a $1,565,298 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) on September 1, 2025. The grant will support research to target the METTL3 protein and overcome drug resistance in metastatic clear cell renal cell carcinoma. The research aims to transform healthcare for military service members, veterans, and the broader public through innovative, advanced...
The University of Texas Health Science Center at Houston (UTHealth) received a $777,586 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, with a performance period from September 30, 2024 to September 29, 2027, will fund the "Stress Inoculation Training (SIT): An Evidence-Driven, Military-Aligned Psychological Performance and Health Sustainment Prototype" research project. The project...
This $1,559,880 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support the "PEGASUS: PREGNANCY COMPLICATIONS IN AYA CANCER SURVIVORS" research project at the University of Texas Health Science Center at Houston (UTHealth). The award, effective April 1, 2025 through March 31, 2029, will fund advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the...
The University of Texas Health Science Center of San Antonio (UTHSCSA) received a $978,159 Project Grant award from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant supports research into purinergic receptor antagonist therapeutics for treating metastatic renal cancer from July 1, 2023 through June 30, 2026. As the prime awardee, UTHSCSA will conduct research to develop medical solutions for cancer on the battlefield and...
This federal Project Grant award of $400,000.00 was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, with a performance period from October 1, 2024 to September 30, 2026. The award supports research by the University of Maryland, Baltimore to develop "drug conjugates of modified LGR4/5/6 ligands for cancer treatment." The university, as the prime awardee, has extensive expertise in biomedical research, clinical trials, and...